ProPhase Labs, Inc. Current Income Tax Expense (Benefit)
ProPhase Labs, Inc. (PRPH) reported Current Income Tax Expense (Benefit) of $45.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-06-01
- ProPhase Labs, Inc. current income tax expense (benefit) for fiscal 2024 was $45.00K, a 95.74% decline from fiscal 2023.
- ProPhase Labs, Inc. current income tax expense (benefit) for fiscal 2023 was $1.06M, a 76.96% decline from fiscal 2022.
- ProPhase Labs, Inc. current income tax expense (benefit) for fiscal 2022 was $4.58M, a 247.72% increase from fiscal 2021.
- ProPhase Labs, Inc. current income tax expense (benefit) for fiscal 2021 was $1.32M, a 10883.33% increase from fiscal 2020.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | $45.00K 10-K · filed 2026-06-01 | |
| 2023-12-31 | $1.06M 10-K · filed 2025-04-01 | |
| 2022-12-31 | $4.58M 10-K · filed 2024-03-29 | |
| 2021-12-31 | $1.32M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $12.00K 10-K · filed 2022-03-31 | |
| 2018-12-31 | $103.00K 10-K · filed 2020-03-26 | |
| 2017-12-31 | -$1.42M 10-K · filed 2019-03-26 | -$17.99M 10-K · filed 2018-03-28 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2012-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2011-12-31 | $0.00 10-K · filed 2014-03-27 | |
| 2010-12-31 | -$40.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |